Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7322
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges ; day:14 ; month:8 ; year:2020 ; pages:1-11
Heart failure reviews ; (14.8.2020), 1-11
- Creator
-
Bruno, Marianna
Castaño, Adam
Burton, Arianna
Grodin, Justin L.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10741-020-10010-8
- URN
-
urn:nbn:de:101:1-2020100718541512578591
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:44 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bruno, Marianna
- Castaño, Adam
- Burton, Arianna
- Grodin, Justin L.
- SpringerLink (Online service)
Other Objects (12)
Diagnosis of Transthyretin Amyloid Cardiomyopathy
Transthyretin Amyloid Cardiomyopathy in a Young Female
Assessment of transthyretin instability in patients with wild-type transthyretin amyloid cardiomyopathy
Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy
Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
Clinical characteristics and prognosis of Chinese patients with hereditary transthyretin amyloid cardiomyopathy
Transthyretin amyloid cardiomyopathy in patients with unexplained increased left ventricular wall thickness
Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis
Treatment of transthyretin (TTR) amyloid cardiomyopathy with an antisense oligonucleotide inhibitor of TTR synthesis
Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy
Estimating the Prevalence of Transthyretin Amyloid Cardiomyopathy in a Large In-Hospital Database in Japan
Multi-modality artificial intelligence-based transthyretin amyloid cardiomyopathy detection in patients with severe aortic stenosis
Diagnosis of Transthyretin Amyloid Cardiomyopathy
Transthyretin Amyloid Cardiomyopathy in a Young Female
Assessment of transthyretin instability in patients with wild-type transthyretin amyloid cardiomyopathy
Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy
Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
Clinical characteristics and prognosis of Chinese patients with hereditary transthyretin amyloid cardiomyopathy
Transthyretin amyloid cardiomyopathy in patients with unexplained increased left ventricular wall thickness
Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis
Treatment of transthyretin (TTR) amyloid cardiomyopathy with an antisense oligonucleotide inhibitor of TTR synthesis
Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy
Estimating the Prevalence of Transthyretin Amyloid Cardiomyopathy in a Large In-Hospital Database in Japan
Multi-modality artificial intelligence-based transthyretin amyloid cardiomyopathy detection in patients with severe aortic stenosis
Diagnosis of Transthyretin Amyloid Cardiomyopathy
Transthyretin Amyloid Cardiomyopathy in a Young Female
Assessment of transthyretin instability in patients with wild-type transthyretin amyloid cardiomyopathy
Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy
Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
Clinical characteristics and prognosis of Chinese patients with hereditary transthyretin amyloid cardiomyopathy
Transthyretin amyloid cardiomyopathy in patients with unexplained increased left ventricular wall thickness
Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis
Treatment of transthyretin (TTR) amyloid cardiomyopathy with an antisense oligonucleotide inhibitor of TTR synthesis
Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy
Estimating the Prevalence of Transthyretin Amyloid Cardiomyopathy in a Large In-Hospital Database in Japan